Congrès ASH 2018 : le rendez-vous annuel incontournable des chercheurs de CALYM

30 novembre 2018,

Du 1er au 4 décembre 2018, aura lieu à San Diego (Etats-Unis), la 60ème édition du congrès international de la société américaine d’hématologie, ASH, rassemblant plus de 20 000 hématologues du monde entier.

Les chercheurs de l’Institut Carnot CALYM y présenteront leurs derniers résultats de recherche sur le lymphome. Quatre communications orales et treize posters ont en effet été sélectionnés.

Les communications orales sont les suivantes :

– “A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B‐Cell Lymphoma in Need of Systemic Therapy”. F Morschhauser et al.(Session 623, le 2/12/18 à 16h45, San Diego Convention Center, Hall AB)

– “Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1‐2 : Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials”. C Laurent et al. (Session 622, le 3/12/18 à 15h30, San Diego Convention Center, Salle 28D)

– “Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T‐Cell Lymphoma (AITL) : Final Analysis of Clinical and Molecular Data of a Phase 2 LYSA Study”. F Lemonnier et al. (Session 624. 3/12/18 à 18h45, San Diego Convention Center, Salle 6F)

– “Desynchronization of the Germinal Center dynamics and remodeling of the tumor microenvironment characterize Kmt2d-driven lymphomagenesis”. G Brisou et al. (Session 621, le 3/12/18 à 11h15, San Diego Convention Center, Salle 28D)

Les posters sont les suivants :

– “Breast Implant Associated‐Anaplastic Large Cell Lymphoma (BIA‐ALCL) : The French Lymphoma Study Association (LYSA) Registry Data.” F Le Bras et al.

– “Superiority of Allogenic Stem Cell Transplantation after Anti‐PD1 Therapy over Anti‐PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma : Real World Evidence from the French Early Access Program.” G Manson et al.

– “Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma‐Genomic Project Conducted on Behalf of the LYSA Group.” Y Le Bris et al.

– “Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno‐Chemotherapy ‐ a Study By the LYSA Group.” Y Le Bris et al.

– “Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study.” AS Cottereau et al.

– “Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the LYSA EORTC 20012 Randomized Protocol.” D Canioni et al.

– “Results from a Phase Ib Evaluation of Tazemetostat (EPZ‐6438) in Combination with RCHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) : a LYSA Study.” C Sarkozy et al.

– “BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma : A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers.” H Ghesquières et al.

– “Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial.” S Le Gouil et al.

– “Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma : A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA.” P Vandenberghe et al.

– “CSF1R and BTK Inhibitions as Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages.” A Papin et al.

– “Sinusoidal Obstruction Syndrom (SOS) : Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin.” PE Debureaux et al.

– “Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma : A Joint KU Leuven and LYSA Study on Circulating Cell Free DNA”. L Buedts et al.

Pour en savoir plus : http://www.hematology.org/Annual-Meeting/